TY - JOUR
T1 - Fusion of the Fc part of human IgG1 to CD14 enhances its binding to gram-negative bacteria and mediates phagocytosis by Fc receptors of neutrophils
AU - Vida, András
AU - Bardoel, Bart
AU - Milder, Fin
AU - Majoros, László
AU - Sümegi, Andrea
AU - Bácsi, Attila
AU - Vereb, György
AU - van Kessel, Kok P M
AU - van Strijp, Jos A G
AU - Antal-Szalmás, Péter
N1 - Copyright © 2012 Elsevier B.V. All rights reserved.
PY - 2012/8/30
Y1 - 2012/8/30
N2 - Microbial resistance to antimicrobial drugs is promoting a search for new antimicrobial agents that target highly conservative structures of pathogens. Human CD14 - a known pattern recognition receptor (PRR) which recognizes multiple ligands from different microbes might be a worthy candidate. The aim of our work was to create a CD14/Fc dimer protein and evaluate its whole bacteria binding and opsonizing capabilities. Fusion of CD14 with the fragment crystallisable (Fc) part of human IgG1 could not only lead to an artificial opsonin but the dimerization through the Fc part might also increase its affinity to different ligands. Human CD14 and the Fc part of human IgG1 was fused and expressed in HEK293 cells. A histidine tagged CD14 (CD14/His) was also expressed as control. Using flow cytometry we could prove that CD14/Fc bound to whole Gram-negative bacteria, especially to short lipopolysaccharide (Ra and Re) mutants, and weak interaction was observed between the fusion protein and . Listeria monocytogenes. Other Gram-positive bacteria and fungi did not show any association with CD14/Fc. CD14/His showed about 50-times less potent binding to Gram-negative bacteria. CD14/Fc acted as an opsonin and enhanced phagocytosis of these bacteria by neutrophil granulocytes, monocyte-derived macrophages and dendritic cells. Internalization of bacteria was confirmed by trypan blue quenching and confocal microscopy. On neutrophils the Fc part of the fusion protein was recognized by Fc receptors (CD16, CD32), as determined by blocking experiments. CD14/Fc enhanced the killing of bacteria in an ex vivo whole blood assay. Our experiments confirm that PRR/Fc fusion proteins can give a boost to FcR dependent phagocytosis and killing provided the antimicrobial part binds efficiently to microbes. © 2012 Elsevier B.V..
AB - Microbial resistance to antimicrobial drugs is promoting a search for new antimicrobial agents that target highly conservative structures of pathogens. Human CD14 - a known pattern recognition receptor (PRR) which recognizes multiple ligands from different microbes might be a worthy candidate. The aim of our work was to create a CD14/Fc dimer protein and evaluate its whole bacteria binding and opsonizing capabilities. Fusion of CD14 with the fragment crystallisable (Fc) part of human IgG1 could not only lead to an artificial opsonin but the dimerization through the Fc part might also increase its affinity to different ligands. Human CD14 and the Fc part of human IgG1 was fused and expressed in HEK293 cells. A histidine tagged CD14 (CD14/His) was also expressed as control. Using flow cytometry we could prove that CD14/Fc bound to whole Gram-negative bacteria, especially to short lipopolysaccharide (Ra and Re) mutants, and weak interaction was observed between the fusion protein and . Listeria monocytogenes. Other Gram-positive bacteria and fungi did not show any association with CD14/Fc. CD14/His showed about 50-times less potent binding to Gram-negative bacteria. CD14/Fc acted as an opsonin and enhanced phagocytosis of these bacteria by neutrophil granulocytes, monocyte-derived macrophages and dendritic cells. Internalization of bacteria was confirmed by trypan blue quenching and confocal microscopy. On neutrophils the Fc part of the fusion protein was recognized by Fc receptors (CD16, CD32), as determined by blocking experiments. CD14/Fc enhanced the killing of bacteria in an ex vivo whole blood assay. Our experiments confirm that PRR/Fc fusion proteins can give a boost to FcR dependent phagocytosis and killing provided the antimicrobial part binds efficiently to microbes. © 2012 Elsevier B.V..
KW - HEK293 cells
KW - cells, cultured
KW - dendritic cells/drug effects
KW - flow cytometry
KW - gene expression/immunology
KW - gram-negative bacteria/drug effects
KW - gram-positive bacteria/drug effects
KW - humans
KW - immunity, innate
KW - immunoglobulin Fc fragments/genetics
KW - immunoglobulin G/chemistry
KW - lipopolysaccharide receptors/genetics
KW - lipopolysaccharides/pharmacology
KW - macrophages/drug effects
KW - neutrophils/drug effects
KW - opsonin proteins/biosynthesis
KW - phagocytosis/immunology
KW - protein binding
KW - receptors, Fc/immunology
KW - recombinant fusion proteins/genetics
KW - transfection
KW - HEK293-cellen
KW - cellen, gekweekt
KW - dendritische cellen/medicijneffecten
KW - eiwitbinding
KW - fagocytose/immunologie
KW - flowcytometrie
KW - genexpressie/immunologie
KW - gram-negatieve bacteriën/medicijneffecten
KW - gram-positieve bacteriën/medicijneffecten
KW - immuniteit, aangeboren
KW - immunoglobuline Fc-fragmenten/genetica
KW - immunoglobuline G/chemie
KW - lipopolysachariden/farmacologie
KW - lipopolysacharidereceptoren/genetica
KW - macrofagen/medicijneffecten
KW - mensen
KW - neutrofielen/medicijneffecten
KW - opsonine-eiwitten/biosynthese
KW - receptoren, Fc/immunologie
KW - recombinante fusie-eiwitten/genetica
KW - transfectie
U2 - 10.1016/j.imlet.2012.04.008
DO - 10.1016/j.imlet.2012.04.008
M3 - Article
C2 - 22575527
SN - 0165-2478
VL - 146
SP - 31
EP - 39
JO - Immunology Letters
JF - Immunology Letters
IS - 1-2
ER -